F. Okabe, Shingo Sato, T. Yanase, Takatoshi Higuchi, K. Komuta, N. Morishita, K. Kawahara, Hidekazu Suzuki
{"title":"卡铂、培美曲塞、派姆单抗联合一线治疗的甲状腺转录因子-1、肿瘤比例评分及治疗效果","authors":"F. Okabe, Shingo Sato, T. Yanase, Takatoshi Higuchi, K. Komuta, N. Morishita, K. Kawahara, Hidekazu Suzuki","doi":"10.2482/haigan.63.15","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Thyroid Transcription Factor-1, Tumor Proportion Score and Treatment Effect in Combination Therapy with Carboplatin, Pemetrexed, and Pembrolizumab as a First-line Therapy\",\"authors\":\"F. Okabe, Shingo Sato, T. Yanase, Takatoshi Higuchi, K. Komuta, N. Morishita, K. Kawahara, Hidekazu Suzuki\",\"doi\":\"10.2482/haigan.63.15\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":35081,\"journal\":{\"name\":\"Japanese Journal of Lung Cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Japanese Journal of Lung Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2482/haigan.63.15\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Lung Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2482/haigan.63.15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Thyroid Transcription Factor-1, Tumor Proportion Score and Treatment Effect in Combination Therapy with Carboplatin, Pemetrexed, and Pembrolizumab as a First-line Therapy